Bioinformatics company ArteraAI partnered with the American Cancer Society to contribute towards making progress against cancer. The partnership with the American Cancer Society aims to improve outcomes and reverse disparities for Black men through its Improving Mortality from Prostate Cancer Together (IMPACT) initiative, which focuses on using innovative technology to increase shared decision-making, treatment adherence, and reducing stigma in marginalized communities.

ArteraAI aims to personalize cancer treatment through the use of AI-based predictive and prognostic cancer tests. Its recent emergence from stealth mode with USD 90 million in funding will support the distribution of its flagship test, the ArteraAI Prostate Test, for prostate cancer and the development of tests to support therapy personalization in other cancers.

California-based Artera is a precision medicine company that is working on AI tests with the aim of customizing treatment options for patients suffering from cancer. The company’s flagship test is a test to identify patients that will benefit from therapy intensification and help guide treatment decisions for men with localized prostate cancer. The test is clinically available through a single CLIA-certified laboratory in Jacksonville, Florida, and costs USD 3,873.